Skip to main content
Publications
Bhashyam SS, Shane LG, Lewis HB, de la Cruz M, Galinsky J , Demchuk K, Waite NM, Lazarus JV, Salisbury DM. Results from the COVID-19 vaccines discrete choice experiment pre-test qualitative interviews in Canada, Germany, the UK, and US general population . Poster presented at the ID Week 2023; October 3, 2023. Washington, DC. [abstract] Open Forum Infect Dis. 2023 Nov 27; 10(Suppl 2):S263-4. doi: 10.1093/ofid/ofad500.1208
Nance R, Vannappagari V, Johannes C , Calingaert B , Saltus C , Boswell S, Rodriguez B, Moore R, Eron J, Geng E, Mathews WC, Saag MS, Kitahata M, Delaney JAC, Crane HM, Centers For AIDS Research Network of Integrated Clinical Systems (CNICS). Viral failure among persons living with HIV initiating dolutegravir-based vs. other recommended regimens in real-world clinical care settings . Poster presented at the IDWeek 2017 Conference; October 2017. San Diego, CA. [abstract] Open Forum Infect Dis. 2017 Oct 4; 4((Suppl 1)):S39. doi: 10.1093/ofid/ofx162.095
Baker M, Jankosky C, Yih K, Gruber S, Li L, Cocoros N, Lipowicz H, Coronel-Moreno C, Feibelmann S, Lin N, McMahill-Walraven C, Menschik D, Selvan M, Selvam N, Tilney RC, Zichittella L, Lee G, Kawai AT . The risk of febrile seizures following influenza and 13-valent pneumococcal conjugate vaccines . Poster presented at the 2017 Infectious Disease Week Conference; October 6, 2017. San Diego, CA. [abstract] Open Forum Infect Dis. 2017 Oct; 4(Suppl 1):S464-5. doi: 10.1093/ofid/ofx163.1187
Yosipovitch G, Reaney M, Mastey V, Eckert L, Nelson L , Clark M , Abbe A, Ardeleanu M, Radin A, Gadkari A. Validation of the peak pruritus numerical rating scale: results from clinical studies of dupilumab in adults with moderate-to-severe atopic dermatitis . Poster presented at the 2017 American Academy of Dermatology Annual Meeting; March 4, 2017. Orlando, FL. [abstract] J Am Acad Dermatol. 2017 Jun; 76(6 Suppl 1):AB278. doi: 10.1016/j.jaad.2017.04.1082
Strober B, Gottlieb AB, Sherif B , Mollon P, Gilloteau I, McLeod L , Fox T, Mordin M , Gnanasakthy A , Papavassilis C, Lebwohl MG. Secukinumab sustains early patient-reported outcome benefits through 1 year: results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept . J Am Acad Dermatol. 2017 Apr;76(4):655-61. doi: 10.1016/j.jaad.2016.11.043
Strober B, Blauvelt A, Zhao Y, Milutinovic M, Mollon P, You R, Sherif B , Williams N, Fox T, Augustin M, Lebwohl M. Secukinumab treatment provides more effective relief from patient-reported psoriasis-related pain, itching, and scaling than ustekinumab . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB273. Previously presented at the 24th European Academy of Dermatology and Venereology Congress. doi: 10.1016/j.jaad.2016.02.1054
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M , Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1049
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B , Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1050
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B , McLeod L , Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1051
Blauvelt A, Korman N, Mollon P, Zhao Y, Milutinovic M, You R, Sherif B , Williams N, Fox T, Augustin M. Secukinumab treatment provides faster and more effective relief from patient-reported quality-of-life impact than ustekinumab in subjects with moderate to severe plaque psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5[S1]):AB273. Previously presented at the 24th European Academy of Dermatology and Venereology Congress. doi: 10.1016/j.jaad.2016.02.1053
Kimball AB, Rothman KJ , Kricorian G, Pariser D, Yamauchi PS, Menter A, Teller CF, Aras G, Accortt NA, Hooper M, Rice KC, Gelfand JM. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results . J Am Acad Dermatol. 2015 Jan;72(1):115-22. doi: 10.1016/j.jaad.2014.08.050